N-(4-cyano-2-ethylbenzyl)phthalimide | 202522-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(4-cyano-2-ethylbenzyl)phthalimide
• 英文别名: 4-[(1,3-Dioxoisoindol-2-yl)methyl]-3-ethylbenzonitrile
• CAS: 202522-06-3
• 化学式: C₁₈H₁₄N₂O₂
• 分子量: 290.321
• InChiKey: OYEZWPNQKZELTL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-cyano-2-ethylbenzyl)phthalimide 在 35percent aq. N₂H₄ 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 8.0h， 生成 3-Ethyl-4-[[[2-(2-methylbutan-2-ylamino)-3,4-dioxocyclobuten-1-yl]amino]methyl]benzonitrile
  参考文献：
  名称：

  Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 2. Selective and Potent Benzylamino Cyclobutenediones

  摘要：

  A novel series of benzylamine, potassium channel openers (KCOs) is presented as part of our program toward designing new, bladder-selective compounds for the treatment of urge urinary incontinence (UUI). We have found that the in vitro potency of (R)-4-[3,4-dioxo-2-(1,2,2-trimethyl-propylamino)-cyclobut-1-enylamino]3-ethyl-benzonitrile 1 in the relaxation of precontracted rat detrusor strips can also be obtained with cyanobenzylamine derivative 4 (IC50 = 0.29 mu M) (Figure 3). Addition of a 2-Cl substituted benzylamine moiety and changing the alkylamino substituent of 4 to a t-Bu amine gives 31 (IC50 = 0.14 mu M)-a compound with similar in vitro potency as 4 as well as relaxant activity on bladder smooth muscle in vivo when administered orally (31, ED50 = 3 mg/kg) in a rodent model of bladder instability. Further modifications, particularly the replacement of the t-Bu amino substituent with a tert-amylamine, gave a similarly active compound 60 (IC50 = 0.10 mu M) which shows excellent in vivo efficacy (ED50 = 0.6 mg/kg). Moreover, 60, 3-(2,4-dichloro-6-methyl-benzylamino)-4- 1,1-dimethylpropylamino)-cyclobut-3-ene-1,2-dione (WAY-151616), shows excellent tissue selectivity for bladder K channels over arterial tissue (60, MAP ED20 = 100 mg/kg; selectivity: MAP ED20/ bladder ED50 = 166). Other manipulations of the benzylamino cyclobutenediones, acylation of the benzylamine, conversion of the benzylamine substituent to a benzamide, homologation of the benzylamine to a phenethylamine, and incorporation of a methyl group at the benzyl carbon, all led to substantial loss of in vitro activity, although some in vivo activity was maintained in the acylated analogues. Compound 60 represents an attractive candidate for development in the treatment of UUI.

  DOI：

  10.1021/jm9905108
• 作为产物：
  描述：

  3-乙基-4-甲酰基苯甲腈 在 sodium tetrahydroborate 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 27.0h， 生成 N-(4-cyano-2-ethylbenzyl)phthalimide
  参考文献：
  名称：

  Design and SAR of Novel Potassium Channel Openers Targeted for Urge Urinary Incontinence. 2. Selective and Potent Benzylamino Cyclobutenediones

  摘要：

  A novel series of benzylamine, potassium channel openers (KCOs) is presented as part of our program toward designing new, bladder-selective compounds for the treatment of urge urinary incontinence (UUI). We have found that the in vitro potency of (R)-4-[3,4-dioxo-2-(1,2,2-trimethyl-propylamino)-cyclobut-1-enylamino]3-ethyl-benzonitrile 1 in the relaxation of precontracted rat detrusor strips can also be obtained with cyanobenzylamine derivative 4 (IC50 = 0.29 mu M) (Figure 3). Addition of a 2-Cl substituted benzylamine moiety and changing the alkylamino substituent of 4 to a t-Bu amine gives 31 (IC50 = 0.14 mu M)-a compound with similar in vitro potency as 4 as well as relaxant activity on bladder smooth muscle in vivo when administered orally (31, ED50 = 3 mg/kg) in a rodent model of bladder instability. Further modifications, particularly the replacement of the t-Bu amino substituent with a tert-amylamine, gave a similarly active compound 60 (IC50 = 0.10 mu M) which shows excellent in vivo efficacy (ED50 = 0.6 mg/kg). Moreover, 60, 3-(2,4-dichloro-6-methyl-benzylamino)-4- 1,1-dimethylpropylamino)-cyclobut-3-ene-1,2-dione (WAY-151616), shows excellent tissue selectivity for bladder K channels over arterial tissue (60, MAP ED20 = 100 mg/kg; selectivity: MAP ED20/ bladder ED50 = 166). Other manipulations of the benzylamino cyclobutenediones, acylation of the benzylamine, conversion of the benzylamine substituent to a benzamide, homologation of the benzylamine to a phenethylamine, and incorporation of a methyl group at the benzyl carbon, all led to substantial loss of in vitro activity, although some in vivo activity was maintained in the acylated analogues. Compound 60 represents an attractive candidate for development in the treatment of UUI.

  DOI：

  10.1021/jm9905108

文献信息

• Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP1151990A1

  公开（公告）日：2001-11-07

  The compounds of the formula: wherein R1, R2, R3 and A are as defined herein are useful, via potassium channel modulation, in the treatment of disorders associated with smooth muscle contraction. Such disorders include, but are not limited to, urinary incontinence, hypertension, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina and cerebral vascular disease.

  式中的化合物 其中 R1、R2、R3 和 A 如本文所定义，通过调节钾通道，可用于治疗与平滑肌收缩有关的疾病。这些疾病包括但不限于尿失禁、高血压、哮喘、早产、肠易激综合征、充血性心力衰竭、心绞痛和脑血管疾病。
• SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0934257A1

  公开（公告）日：1999-08-11
• US5780505A
  申请人：——

  公开号：US5780505A

  公开（公告）日：1998-07-14
• [EN] SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES<br/>[FR] DERIVES A SUBSTITUTION N-ARYLMETHYLAMINO DE CYCLOBUTENE-3,4-DIONES
  申请人：——

  公开号：WO1998002413A1

  公开（公告）日：1998-01-22

  [EN] The compounds of formula (I) wherein R1, R2, R3 and A are as defined herein are useful, via potassium channel modulation, in the treatment of disorders associated with smooth muscle contraction. Such disorders include, but are not limited to, urinary incontinence, hypertension, asthma, premature labor, irritable bowel syndrome, congestive heart failure, angina and cerebral vascular disease.
  [FR] L'invention porte sur des composés de formule (I) dans laquelle R1, R2, R3 et A sont tels que définis dans la description, et qui s'avèrent utiles, par modulation des canaux potassium, pour le traitement de troubles associés à la contraction des muscles lisses. Lesdits troubles comprennent non limitativement: l'incontinence urinaire, l'hypertension, l'asthme, l'accouchement prématuré, le côlon irritable, l'insuffisance cardiaque globale, l'angor et les affections vasculaires cérébrales.